📇 Rhumatologue · FREJUS · (83) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
6 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
118.8 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CABINET DU DR Delia CONSTANTINESCU
POLE SANTE TASSIGNY 1591 AV MAL DE LATTRE DE TASSIGNY, 83600 FREJUS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Stem cells translational medicine · 2024
Abstract A limited number of tissues can spontaneously regenerate following injury, and even fewer can regenerate to a state comparable to mature, healthy adult tissue. Mesenchymal stem cells (MSCs) were first described in the 1960s-1970s by Friedenstein et al as a small population of bone marrow cells with osteogenic potential and abilities to differentiate into chondrocytes. In 1991, Arnold Caplan coined the term “mesenchymal cells” after identifying these cells as a theoretical precursor to bone, cartilage, tendon, ligament, marrow stroma, adipocyte, dermis, muscle, and connective tissues. MSCs are derived from periosteum, fat, and muscle. Another attractive property of MSCs is their immunoregulatory and regenerative properties, which result from crosstalk with their microenvironment and components of the innate immune system. Collectively, these properties make MSCs potentially attractive for various therapeutic purposes. MSCs offer potential in sports medicine, aiding in muscle recovery, meniscal tears, and tendon and ligament injuries. In joint disease, MSCs have the potential for chondrogenesis and reversing the effects of osteoarthritis. MSCs have also demonstrated potential application to the treatment of degenerative disc disease of the cervical, thoracic, and lumbar spine.
Journal of clinical medicine · 2025
Background/Objectives: Atopy and spondyloarthritis (SpA) are immune-mediated diseases driven by distinct T-helper (Th) cell pathways—Th2 for atopy and Th1/Th17 for SpA. The coexistence of these divergent immune responses is increasingly recognized, particularly in the context of biological therapies that target pro-inflammatory cytokines. This study aimed to investigate Th2 cytokine profiles (IL-4, IL-5, IL-13) in atopic SpA patients receiving biological therapy to better understand how such treatment may influence immune regulation in this complex clinical setting. Methods: We conducted a prospective observational cross-sectional study on 136 SpA patients stratified by biological therapy and atopy status. Serum IL-4, IL-5, and IL-13 levels were quantified using LUMINEX immunoassays. Patients were grouped into biologically treated (BT) and Bio-Naïve (BN) cohorts and further sub-categorized by atopic phenotype (allergic rhinitis, asthma, dermatitis). Statistical comparisons of cytokine levels were made using SPSS IBM version 26 to explore associations with clinical and demographic variables. Results: IL-13 levels were significantly elevated in BT-atopic patients, particularly those with allergic rhinitis and atopic dermatitis, suggesting biological therapy may modulate Th2 responses. IL-5 remained elevated in allergic asthma cases despite treatment, indicating persistent eosinophilic activity. No significant correlation was found between cytokine levels and disease duration or therapy length. Conclusions: Biological therapy in SpA may influence Th2 cytokine expression, notably IL-13, in atopic patients. These findings underscore the importance of immune profiling in guiding personalized treatment strategies and highlight the need for further investigation into the long-term immunomodulatory effects of biologics in patients with overlapping Th1/Th2-driven diseases.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2026 · Journal Article
Geller JS, Samineni A, Swonger RM, Constantinescu D, et al.
Journal of clinical medicine · 2025 · Journal Article
Strugariu G, Pomirleanu C, Russu M, Lapuste V, et al.
Stem cells translational medicine · 2024 · Journal Article
Trapana J, Weinerman J, Lee D, Sedani A, et al.
Medicina interna · 1963 · Journal Article
OPREANU I, CONSTANTINESCU D, GHENTU E
World journal of orthopedics · 2022 · Case Reports
Pavlis W, Constantinescu DS, Murgai R, Barnhill S, et al.
The Journal of arthroplasty · 2026 · Clinical Trial, Phase III
Rizzo MG, Costello JP 2nd, Constantinescu DS, Samineni AV, et al.
✨ Profil synthétique
IA · 05/06/2026MME Delia-Iedida CONSTANTINESCU est une rhumatologue exerçant à FREJUS en libéral. Ses publications sur PubMed incluent des cas cliniques et des essais cliniques, reflétant son engagement dans la recherche et la pratique médicale. Elle contribue ainsi à l'avancement des connaissances dans le domaine de la rhumatologie.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.